The DOI matches its Crossref record, with a small difference in title or year; 14 of the 14 references it cites were found in a registry or an index.
The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6–HDL and LDL Treatment Strategies in Atherosclerosis)
Open accessAbstract
Objectives This report describes the final results of the ARBITER 6-HALTS (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis) trial.Background The ARBITER 6-HALTS trial was terminated early on the basis of a pre-specified interim analysis showing superiority of niacin over ezetimibe on change in carotid intima-media thickness (CIMT). After termination, an additional 107 subjects completed a close-out assessment.Methods Patients with coronary heart disease (CHD) or CHD equivalent with low-density lipoprotein cholesterol <100 mg/dl and high-density lipoprotein cholesterol <50 mg/dl for men or 55 mg/dl for women while receiving stable statin treatment were randomly assigned to ezetimibe (10 mg/day) or extended-release niacin (target dose, 2,000 mg/day). The primary end point was change in mean CIMT, analyzed according to a last observation carried forward method. The relationships of study medication adherence, dosage, and cumulative exposure (product of adherence, dose, and time) with change in CIMT were explored.Results Results in 315 patients included 208 with 14-month follow-up and 107 after mean treatment of 7 +/- 3 months. Niacin (n = 154) resulted in significant reduction (regression) in mean CIMT (-0.0102 +/- 0.0026 mm; p < 0.001) and maximal CIMT (-0.0124 +/- 0.0036 mm; p = 0.001), whereas ezetimibe (n = 161) did not reduce mean CIMT (-0.0016 +/- 0.0024 mm; p = 0.88) or maximal CIMT (-0.0005 +/- 0.0029 mm; p = 0.88) compared with baseline. There was a significant difference between ezetimibe and niacin treatment groups on mean changes in CIMT, favoring niacin, for both mean CIMT (p = 0.016) and maximal CIMT (p = 0.01). Increased cumulative drug exposure was related to regression of CIMT with niacin, and progression of CIMT with ezetimibe.Conclusions Niacin induces regression of CIMT and is superior to ezetimibe for patients taking statins. (Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis; NCT00397657).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6: HDL and LDL Treatment Strategies in Atherosclerosis (ARBITER-6 HALTS) trial with 315 patients, ER nicotinic acid was shown to be more effective than ezetimibe at reducing CIMT on a background of statin therapy in patients with LDL-C ,2.5 mmol/L (less than 100 mg/dL).134”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [134]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
Clofibrate and Niacin in Coronary Heart Disease
Stamler, J. (1975) · JAMA · doi:10.1001/jama.1975.03240160024021 · Cited by 1,750
The Role of Carotid Arterial Intima-Media Thickness in Predicting Clinical Coronary Events
Hodis, H. N., Mack, W. J., LaBree, L., Selzer, R. H., Liu, C.-R., Liu, C.-H., & Azen, S. P. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-4-199802150-00002 · Cited by 1,217
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2
Taylor, A. J., Sullenberger, L. E., Lee, H. J., Lee, J. K., & Grace, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000148955.19792.8d · Cited by 888
Self-citationCrouse, J. R., Raichlen, J. S., Riley, W. A., Evans, G. W., Palmer, M. K., O’Leary, D. H., Grobbee, D. E., Bots, M. L., & for the METEOR Study Group (2007) · JAMA · doi:10.1001/jama.297.12.1344 · Cited by 708
Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness
Taylor, A. J., Villines, T. C., Stanek, E. J., Devine, P. J., Griffen, L., Miller, M. J., Weissman, N. J., & Turco, M. A. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907569 · Cited by 638
Self-citationTaylor, A. J., Lee, H. J., & Sullenberger, L. E. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x148508 · Cited by 303
Self-citation
Cited by
Sorted by citations
Items 201–223 of 223
Optimal use of lipid-altering therapy: guidelines versus evidence
Hilleman, D. E. (2013) · Clinical Lipidology · doi:10.2217/clp.13.18
Beleslin, B., Deljanin, M., Kanjuh, V., Parapid, B. J., Giga, V. L., Prostran, M. S., Angelkov, L., Balinovac, J., Bikicki, M., Ambrosio, G., et al. (2013)
Immediate release niacin effect at stratified lipid levels
Vo, E., & Goldberg, S. J. (2015) · IJC Metabolic & Endocrine · doi:10.1016/j.ijcme.2015.10.004
Statin prescribing in Australian and Irish general practice:a qualitative study
Montgomery, B. (2012) · UWA Profiles and Research Repository (University of Western Australia)
[What is the future for niacin after the AIM-HIGH study?].
Cybulska, B., & Kłosiewicz−Latoszek, L. (2012) · PubMed
Ezetimibe in the Treatment of Patients with Metabolic Diseases
Nehme, M., Upadhyay, A., & Medicine, R. I. I. (2010) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2013.09.01.55
Therapy to Manage Low High-Density Lipoprotein Cholesterol and Elevated Triglycerides
Davidson, M. H. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0101-8.00025-4
Clinical investigation of subclinical vascular disease in psychosocial stress and dyslipidaemia
Ellins, E. A. (2016) · ORCA Online Research @Cardiff (Cardiff University)
Adjuvant Therapy for Incremental Low-Density Lipoprotein Cholesterol Reduction With Ezetimibe
Fernández‐Liz, E., Colomer, M. E. B., Bendahan, G., Roch, M., & Vallés, J. (2017) · Clinical Medicine Insights Therapeutics · doi:10.1177/1179559x17695550
Ruixiao, H., Peipei, L., Yajing, W., & Wu, J. (2019) · Research Square · doi:10.21203/rs.2.294/v1
Bauer, M., Hoffmann, B. H., Möhlenkamp, S., Lehmann, N., Moebus, S., Roggenbuck, U., Berg, C., Kälsch, H., Mahabadi, A. A., Kara, K., et al. (2013) · Herz
Prévalence de la dyslipidémie chez le diabétique âgé
Charrada, I., Alaya, W., Boubaker, F., Zantour, B., & Sfar, H. (2021) · Annales d Endocrinologie · doi:10.1016/j.ando.2021.08.634
FRCP, D. L. M. (2017) · Wiley eBooks · doi:10.1002/9781119052210.ch12
Block, J. H. (2017) · Kirk-Othmer Encyclopedia of Chemical Technology · doi:10.1002/0471238961.1921182219031520.a01.pub3
Non-Statin Treatment of Dyslipidemia
Goldberg, S. J. (2015) · Springer eBooks · doi:10.1007/978-3-319-11161-2_12
Sohouli, M. H., Tavakoli, S., Reis, M. G., Hekmatdoost, A., & Guimarães, N. S. (2024) · Figshare · doi:10.6084/m9.figshare.26094488
Sohouli, M. H., Tavakoli, S., Reis, M. G., Hekmatdoost, A., & Guimarães, N. S. (2024) · Figshare · doi:10.6084/m9.figshare.26738268
Sohouli, M. H., Tavakoli, S., Reis, M. G., Hekmatdoost, A., & Guimarães, N. S. (2024) · Figshare · doi:10.6084/m9.figshare.26738271
Sohouli, M. H., Tavakoli, S., Reis, M. G., Hekmatdoost, A., & Guimarães, N. S. (2024) · Figshare · doi:10.6084/m9.figshare.26094402
HDL and Cardiovascular Disease: Mechanisms, Therapeutic Advances, and Challenges
Sen, K., & Sinha, A. (2026) · Proceedings of the Zoological Society · doi:10.1007/s12595-026-00609-4
Hourcade‐Potelleret, F. (2012) · theses.fr (ABES) · doi:10.70675/e78e3f4az1aadz47d6z9a8bz8dd0e636d743
Cerebrovascular integrity maintenance and inflammation in atherosclerosis animal models
Cataldo, V. D. (2016) · theses.fr (ABES) · doi:10.70675/7b5a6c4bz3377z40fezbf48z5da7afd1a502
Non-statin Therapies for CKD with Dyslipidemia
Mucsi, I. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0515-7_9
Metadata
- Authors
- Villines, T. C., Stanek, E. J., Devine, P. J., Turco, M., Miller, M., Weissman, N. J., Griffen, L., & Taylor, A. J.
- Affiliations
- Walter Reed National Military Medical Center (US)
- Washington Adventist Hospital (US)
- University of Maryland Medical Center (US)
- MedStar Washington Hospital Center (US)
- Corresponding author
- Villines, Todd C.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2010-06
- Volume
- 55
- Issue
- 24
- Pages
- 2721-2726
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2187593761
- Cited by
- 223
- References
- 14
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 5 · 2022: 2 · 2021: 5 · 2020: 10 · 2019: 7 · 2018: 3 · 2017: 6 · 2016: 12 · 2015: 11 · 2014: 20 · 2013: 33 · 2012: 40
- FWCI
- 46.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Henry M. Jackson Foundation
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- nicotinic acid, ezetimibe, carotid intima-media thickness, atherosclerosis, coronary artery disease, statin-treated patients, LDL cholesterol, HDL cholesterol, medication adherence, cumulative drug exposure, atherosclerosis regression, lipid-lowering therapy, trial termination, cardiovascular risk reduction, statin-sparing therapy
- MeSH terms
- Ezetimibe, Aged, Anticholesteremic Agents, Azetidines, Coronary Disease, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Niacin, Time Factors, Ultrasonography, Single-Blind Method, Treatment Outcome, Carotid Artery, Common, Tunica Intima, Atherosclerosis, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
